Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Health Behavior Intervention for Colorectal Cancer Patients

NCT07632313 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-06-15
Last updated
2026-06-08

Condition(s) studied

Colorectal Cancer

Investigational drug(s) / intervention(s)

health behavior intervention programs based on the temporal self-regulation theory are also received

health behavior intervention programs based on the temporal self-regulation theory are also received: The intervention group received additional health behavior intervention programs based on the temporal self-regulation theory in addition to the routine post-operative health education services provided by the hospital. The intervention period was set as 1 session per week for a total of 6 weeks, each session lasting approximately 45-60 minutes. The intervention was conducted in a combination of offline and online guidance and support. Before the intervention, baseline assessments were conducted for the research subjects, and intervention manuals, demonstration videos, and other tools were distributed. From the 1st to the 5th week, corresponding module measures were implemented according to the intervention framework, including looking to the future, intention strengthening, habit shaping, and self-control. In the 6th week, progress summaries, feedback, and long-term plan formulation were carried out. Throughout the process, online WeChat/QQ support groups/Tencent Meeting were u

Study summary

Develop a health behavior intervention plan based on patients' needs and preferences, and preliminarily apply and evaluate the feasibility and effectiveness of this intervention plan for patients with colorectal cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: Age ≥ 18 years; patients who meet the diagnostic criteria for colorectal cancer outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Colorectal Cancer (2023 Edition)" and for whom the time since surgery is ≥ 3 months; patients who are able to understand the study and complete the questionnaire independently; and patients who voluntarily agree to participate. Exclusion Criteria: Patients with severe cardiac, hepatic, or renal insufficiency or other serious systemic diseases; patients with cognitive or psychiatric disorders; patients with severe postoperative complications (such as anastomotic leakage or severe wound infection); patients with metastatic cancer or concurrent malignant tumors; patients with a life expectancy of less than 6 months.

Primary outcome measure(s)

  • health behavior — From before the intervention (T0) to 3 months after the intervention (T2)
    Measured through the Health Behavior Scale for Cancer Patient

Trial sites (1)

FacilityCityRegionStatus
101 Longmian Avenue, Jiangning District Nanjing Jiangsu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07632313 on ClinicalTrials.gov ↗ ← All trials in China